[go: up one dir, main page]

MXPA03001057A - Metodo para tratar desordenes relacionados con la angiogenesis. - Google Patents

Metodo para tratar desordenes relacionados con la angiogenesis.

Info

Publication number
MXPA03001057A
MXPA03001057A MXPA03001057A MXPA03001057A MXPA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A MX PA03001057 A MXPA03001057 A MX PA03001057A
Authority
MX
Mexico
Prior art keywords
related disorders
treating angiogenesis
angiogenesis
treating
nepafenac
Prior art date
Application number
MXPA03001057A
Other languages
English (en)
Inventor
Gustav Graff
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA03001057A publication Critical patent/MXPA03001057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se da a conocer el uso de los acidos 3-benzoilfenilacetico y sus derivados, que incluyen el nepafenac, para tratar desordenes relacionados con la angiogenesis, que incluyen los desordenes oftalmicos, tal como la retinopatia diabetica y la degeneracion macular exudativa.
MXPA03001057A 2000-08-14 2001-08-13 Metodo para tratar desordenes relacionados con la angiogenesis. MXPA03001057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22513300P 2000-08-14 2000-08-14
PCT/US2001/025318 WO2002013804A2 (en) 2000-08-14 2001-08-13 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid

Publications (1)

Publication Number Publication Date
MXPA03001057A true MXPA03001057A (es) 2004-09-10

Family

ID=22843668

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001057A MXPA03001057A (es) 2000-08-14 2001-08-13 Metodo para tratar desordenes relacionados con la angiogenesis.

Country Status (18)

Country Link
US (1) US20020037929A1 (es)
EP (1) EP1309323B1 (es)
JP (2) JP5586117B2 (es)
KR (1) KR20030017653A (es)
CN (1) CN1447688A (es)
AR (1) AR030345A1 (es)
AT (1) ATE345123T1 (es)
AU (2) AU8333701A (es)
BR (1) BR0113204A (es)
CA (1) CA2417282C (es)
DE (1) DE60124560T2 (es)
DK (1) DK1309323T3 (es)
ES (1) ES2275710T3 (es)
MX (1) MXPA03001057A (es)
PL (1) PL366220A1 (es)
PT (1) PT1309323E (es)
WO (1) WO2002013804A2 (es)
ZA (1) ZA200300782B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
KR20050043923A (ko) * 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
CA2504460A1 (en) * 2002-11-12 2004-05-27 Peter G. Klimko Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
DE122011100019I1 (de) 2003-01-21 2011-11-03 Senju Pharma Co Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
PL1809270T3 (pl) * 2004-11-09 2010-08-31 Alcon Inc Kwas 5,6,7-trihydroksyheptanowy i jego analogi do leczenia chorób oczu i chorób związanych z odpowiedziami hiperproliferacyjnymi i angiogenicznymi
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
US20100292289A1 (en) * 2007-11-30 2010-11-18 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with novel amides
KR20100135748A (ko) * 2008-02-21 2010-12-27 센주 세이야꾸 가부시키가이샤 아쥬반트로서의 안과용 ｎｓａｉｄ
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577461A5 (es) * 1975-08-13 1976-07-15 Robins Co Inc A H
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
KR100732262B1 (ko) * 1999-10-21 2007-06-25 알콘, 인코퍼레이티드 약물 전달 장치
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU1051201A (en) * 1999-11-11 2001-06-06 Wireless Methods Ltd. Remote switching and actuation of electrical devices

Also Published As

Publication number Publication date
AU8333701A (en) 2002-02-25
DK1309323T3 (da) 2007-03-19
ES2275710T3 (es) 2007-06-16
DE60124560T2 (de) 2007-09-06
WO2002013804A2 (en) 2002-02-21
PL366220A1 (en) 2005-01-24
US20020037929A1 (en) 2002-03-28
JP2004520267A (ja) 2004-07-08
JP2012193214A (ja) 2012-10-11
HK1057331A1 (en) 2004-04-02
DE60124560D1 (de) 2006-12-28
WO2002013804A3 (en) 2002-06-06
AU2001283337B2 (en) 2006-06-15
AR030345A1 (es) 2003-08-20
KR20030017653A (ko) 2003-03-03
JP5586117B2 (ja) 2014-09-10
BR0113204A (pt) 2006-02-21
EP1309323A2 (en) 2003-05-14
ZA200300782B (en) 2004-08-27
CN1447688A (zh) 2003-10-08
PT1309323E (pt) 2007-01-31
ATE345123T1 (de) 2006-12-15
CA2417282C (en) 2009-12-22
CA2417282A1 (en) 2002-02-21
EP1309323B1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
ECSP055524A (es) Derivados de indolin-fenilsufonamida
CR7673A (es) Antranilamidopirimidinas que inhiben vegfr-2 y vegfr-3
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
PA8541601A1 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
MXPA03001057A (es) Metodo para tratar desordenes relacionados con la angiogenesis.
HN1999000124A (es) Derivados de pirazol substituido.
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2192301T3 (es) Derivados de resorcinol.
ES2161290T3 (es) Derivados de quinazolina.
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
UY28294A1 (es) Dihidroquinazolinas sustituidas
UY28126A1 (es) Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
PA8548501A1 (es) Nuevos derivados de acido sulfonico
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
UY26951A1 (es) Derivados de ácido propiónico
ES2149037T3 (es) Emulsion que contiene acido ascorbico y sus utilizaciones en los ambitos cosmetico y dermatologico.
AR030346A1 (es) Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
ES2081916T3 (es) Delta-lactonas naturales y procedimiento para su fabricacion.
ES2185837T3 (es) Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
PA8511401A1 (es) Nuevos derivados de amidas heterociclicas

Legal Events

Date Code Title Description
FG Grant or registration